Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 544 of the 545 references it cites were found in a registry or an index, and 1 are not checked yet.

A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates

Open access
Brand, Sarel, Moller, Marisa, Harvey, Brian·2015·Current Neuropharmacology

Abstract

Despite significant research efforts aimed at understanding the neurobiological underpinnings of mood (depression, bipolar disorder) and psychotic disorders, the diagnosis and evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms as well as psychometric evaluations. Therefore, biological markers aimed at improving the current classification of psychotic and mood-related disorders, and that will enable patients to be stratified on a biological basis into more homogeneous clinically distinct subgroups, are urgently needed. The attainment of this goal can be facilitated by identifying biomarkers that accurately reflect pathophysiologic processes in these disorders. This review postulates that the field of psychotic and mood disorder research has advanced sufficiently to develop biochemical hypotheses of the etiopathology of the particular illness and to target the same for more effective disease modifying therapy. This implies that a "one-size fits all" paradigm in the treatment of psychotic and mood disorders is not a viable approach, but that a customized regime based on individual biological abnormalities would pave the way forward to more effective treatment. In reviewing the clinical and preclinical literature, this paper discusses the most highly regarded pathophysiologic processes in mood and psychotic disorders, thereby providing a scaffold for the selection of suitable biomarkers for future studies in this field, to develope biomarker panels, as well as to improve diagnosis and to customize treatment regimens for better therapeutic outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x13666150307004545

Cites

544 of 545 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) Glutamate-mediated effects on the cGMP-NO system leading to monoamine release that in turn can be targeted by pharmacological means, eg. PDE5 and NOS inhibitors, as well as known antidepressants. However this pathway can also lead to oxidative stress if excessive glutamate-mediated NO synthesis combines with O2- from aerobic metabolism. Also depicted is the effect of inflammatory mediators that promote iNOS-mediated NO synthesis thereby promoting the formation of cell-damaging reactive oxygen and nitrogen species. These pro-oxidative mechanisms can be abrogated by endogenous antioxidant systems such as superoxide dismutase (SOD) and glutathione that act as a sink to quench excessive NO and/or O2-. Abbreviations: calmodulin (Calm); cyclic guanosine monophosphate (cGMP); endoplasmic reticulum (ER); glutamate (Glu); glutathione peroxidase (glut peroxidase); guanosine triphosphate (GTP); inducible nitric oxide synthase (iNOS); l-arginine (L-arg); neuronal nitric oxide synthase (nNOS); nitric oxide (NO); NMDA receptor (NMDAR); phosphodiesterase (PDE); superoxide dismutase (SOD); superoxide (O2-); hydrogen peroxide (H2O2).
Fig. (1) Glutamate-mediated effects on the cGMP-NO system leading to monoamine release that in turn can be targeted by pharmacological means, eg. PDE5 and NOS inhibitors, as well as known antidepressants. However this pathway can also lead to oxidative stress if excessive glutamate-mediated NO synthesis combines with O2- from aerobic metabolism. Also depicted is the effect of inflammatory mediators that promote iNOS-mediated NO synthesis thereby promoting the formation of cell-damaging reactive oxygen and nitrogen species. These pro-oxidative mechanisms can be abrogated by endogenous antioxidant systems such as superoxide dismutase (SOD) and glutathione that act as a sink to quench excessive NO and/or O2-. Abbreviations: calmodulin (Calm); cyclic guanosine monophosphate (cGMP); endoplasmic reticulum (ER); glutamate (Glu); glutathione peroxidase (glut peroxidase); guanosine triphosphate (GTP); inducible nitric oxide synthase (iNOS); l-arginine (L-arg); neuronal nitric oxide synthase (nNOS); nitric oxide (NO); NMDA receptor (NMDAR); phosphodiesterase (PDE); superoxide dismutase (SOD); superoxide (O2-); hydrogen peroxide (H2O2).CC BY-NC · PubMed Central
Fig. (2) An overview of key neuroprotective and neurotoxic molecules involved in drug (antidepressant, lithium etc.)-induced neuroplasticity. The monoaminergic system mainly exerts its effect on BDNF expression via the cAMP cascade, while BDNF in turn exerts its effect on monoaminergic neurons through the TrkB-receptor via the MAPK/ERK cascade and the phospholipase C (PLC) signalling system. Adapted from [342]. Abbreviations: beta adrenoceptor (βAR); alpha-2 adrenoceptor (α2AR); BDNF receptor (TrkB), see text for further details/ abbreviations not noted here.
Fig. (2) An overview of key neuroprotective and neurotoxic molecules involved in drug (antidepressant, lithium etc.)-induced neuroplasticity. The monoaminergic system mainly exerts its effect on BDNF expression via the cAMP cascade, while BDNF in turn exerts its effect on monoaminergic neurons through the TrkB-receptor via the MAPK/ERK cascade and the phospholipase C (PLC) signalling system. Adapted from [342]. Abbreviations: beta adrenoceptor (βAR); alpha-2 adrenoceptor (α2AR); BDNF receptor (TrkB), see text for further details/ abbreviations not noted here.CC BY-NC · PubMed Central
Fig. (3) A simplified diagram of the kynurenine pathway, indicating the principle enzymes, IDO and tryptophan-2,3-dioxygenase (TDO), and the subsequent formation of kynurenine and its metabolites from TRP. The diagram indicates the inter-relationship of kynurenine metabolites, particularly QA, kynurenic acid and 3-hydroxyanthranilic acid. This diagram also depicts the activation and inhibition of IDO via pro- and anti-inflammatory cytokines respectively, as well as the influence of oxidative stress processes that will eventually determine cellular resilience or susceptibility to neurotoxic insults. Increased activity of the tryptophan-kynurenine synthesis (by TDO/IDO) will also diminish the availability of tryptophan for serotonin synthesis via tryptophan-5-hydroxylase, with resulting effects on mood and behavior. Abbreviations: glutathione (GSH); interferon (IFN)-γ; interleukin (IL)-2 and -4; nitric oxide synthase (NOS); reactive oxygen species (ROS); serotonin (5-HT); tumour necrosis factor (TNF)-α. Adapted from [452, 453].
Fig. (3) A simplified diagram of the kynurenine pathway, indicating the principle enzymes, IDO and tryptophan-2,3-dioxygenase (TDO), and the subsequent formation of kynurenine and its metabolites from TRP. The diagram indicates the inter-relationship of kynurenine metabolites, particularly QA, kynurenic acid and 3-hydroxyanthranilic acid. This diagram also depicts the activation and inhibition of IDO via pro- and anti-inflammatory cytokines respectively, as well as the influence of oxidative stress processes that will eventually determine cellular resilience or susceptibility to neurotoxic insults. Increased activity of the tryptophan-kynurenine synthesis (by TDO/IDO) will also diminish the availability of tryptophan for serotonin synthesis via tryptophan-5-hydroxylase, with resulting effects on mood and behavior. Abbreviations: glutathione (GSH); interferon (IFN)-γ; interleukin (IL)-2 and -4; nitric oxide synthase (NOS); reactive oxygen species (ROS); serotonin (5-HT); tumour necrosis factor (TNF)-α. Adapted from [452, 453].CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 535 references

Research works printed but not linked: 7

  1. [11]Connor T.J. Leonard B.E. Handbook of Experimental Pharmacology. Antidepressants. Past, Present and Future; 2004 New York Springer
  2. [236]Wegener G. Harvey B.H. Bonefeld B. Müller H.K. Volke V. Overstreet D.H. Elfving B. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int. J. Neuropsychopharmacol. 2010 13 4 461 473 10.1017/S1461145709990241 19627650 · DOI
  3. [310]Jornada L.K. Moretti M. Valvassori S.S. Ferreira C.L. Padilha P.T. Arent C.O. Fries G. R. Kapczinski F. Quevedo J. 2006 19954800
  4. [333]Nestler E.J. Barrot M. DiLeone R.J. Eisch A.J. Gold S.J. Monteggia L.M. Neurobiology of depression. Neuron 2002 34 1 13 25 10.1016/S0896-6273(02)00653-0 11931738 · DOI · Paper page
  5. [374]Dhir A. Kulkarni S.K. Nitric oxide and major depression. Nitric Oxide 2011 24 3 125 131 10.1016/j.niox.2011.02.002 21335097 · DOI · Paper page
  6. [428]Capuron L. Su S. Miller A.H. Bremner J.D. Goldberg J. Vogt G.J. Maisano C. Jones L. Murrah N.V. Vaccarino V. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol. Psychiatry 2008 64 10 896 900 10.1016/j.biopsych.2008.05.019 18597739 PMC2621309 · DOI · Paper page
  7. [544]García-Bueno B. Pérez-Nievas B.G. Leza J.C. Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases? Int. J. Neuropsychopharmacol. 2010 13 10 1411 1429 10.1017/S1461145710000970 20800014 · DOI

Cited by

See all 99

Metadata

Authors
Brand, S., Moller, M., & Harvey, B.
Affiliations
North-West University (ZA)
Corresponding author
Harvey, Brian
Venue
Current Neuropharmacology
Published
2015-07-14
Volume
13
Issue
3
Pages
324-368
ISSN
1570-159X (ISSN-L)
OpenAlex
W2327026140
Cited by
95
References
535
Citations by year
2026: 3 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 16 · 2020: 8 · 2019: 7 · 2018: 13 · 2017: 10 · 2016: 6
FWCI
6.97
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Boloka Institutional Repository (North-west University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
biomarkers, mood disorders, psychosis, depression, bipolar disorder, pathophysiology, biomarker panel, personalized treatment, diagnosis, etiopathogenesis
MeSH terms
Affect, Animals, Bipolar Disorder, Depressive Disorder, Humans, Psychotic Disorders, Antipsychotic Agents, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. https://app.cochat.ai/papers/10.2174/1570159x13666150307004545
The paper
Brand, S., Moller, M., & Harvey, B. (2015). A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666150307004545

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.